BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 96 filers reported holding BIOXCEL THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,152,677 | -38.9% | 623,525 | +71.3% | 0.00% | -50.0% |
| Q1 2023 | $6,793,845 | -30.5% | 364,086 | -20.0% | 0.00% | -33.3% |
| Q4 2022 | $9,781,262 | +82.3% | 455,366 | +0.3% | 0.00% | +50.0% |
| Q3 2022 | $5,365,000 | -3.9% | 453,877 | +7.3% | 0.00% | 0.0% |
| Q2 2022 | $5,584,000 | -37.3% | 423,021 | -0.7% | 0.00% | -33.3% |
| Q1 2022 | $8,911,000 | +5.8% | 426,177 | +2.8% | 0.00% | +50.0% |
| Q4 2021 | $8,426,000 | -33.5% | 414,484 | -0.7% | 0.00% | -50.0% |
| Q3 2021 | $12,671,000 | +51.5% | 417,510 | +45.1% | 0.00% | +100.0% |
| Q2 2021 | $8,362,000 | -32.9% | 287,752 | -0.3% | 0.00% | -50.0% |
| Q1 2021 | $12,456,000 | -8.8% | 288,605 | -2.4% | 0.00% | 0.0% |
| Q4 2020 | $13,656,000 | +8.6% | 295,574 | +1.9% | 0.00% | -20.0% |
| Q3 2020 | $12,579,000 | -20.2% | 290,117 | -2.4% | 0.01% | -16.7% |
| Q2 2020 | $15,757,000 | +156.9% | 297,245 | +8.3% | 0.01% | +100.0% |
| Q1 2020 | $6,133,000 | – | 274,404 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |